No­var­tis' CAR-T fails to help a vul­ner­a­ble group of NHL pa­tients — quash­ing hope of mov­ing up lines of treat­ment

No­var­tis’ ef­forts to move its CAR-T in­to ear­li­er lines of treat­ment have hit a brick wall.

Kym­ri­ah, its pi­o­neer­ing CD19-tar­get­ing ther­a­py, has failed to bend …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER